Developing Rapid-Acting Treatments for Neuropsychiatric Diseases

See latest data
Our Focus

TSND-201 (methylone)
a rapid-acting neuroplastogen
for PTSD

We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. 
Learn More
News

The Latest From Transcend

Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data Read More
Media

Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data
TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1) Read More
Poster Presentation

TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)
Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1 Read More
Press Release

Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1
Methylone: Distinct Pharmacological and Mechanistic Effects Compared with MDMA Read More
Poster Presentation

Methylone: Distinct Pharmacological and Mechanistic Effects Compared with MDMA
Learn More
Our Mission

Striving for a world without neuropsychiatric disease.

Because 1 billion patients
deserve better.
Careers

Help us bring new mental health solutions to patients

Join us in creating a world free from neuropsychiatric disease.
Learn More